cMyc Cancer Research Results

cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
Mye, Myeloma: Click to Expand ⟱

Myeloma - Plasma Cell Malignancy

Alternative Names: Multiple myeloma, plasma cell myeloma

Type: Hematologic malignancy / plasma cell cancer

Origin: Malignant transformation and clonal expansion of antibody-producing plasma cells, usually within the bone marrow.

Function/Characteristics: Myeloma cells produce monoclonal immunoglobulins or light chains and can disrupt normal bone marrow function, bone remodeling, renal function, and immune regulation.

Common Features: Bone marrow infiltration, osteolytic bone lesions, anemia, elevated monoclonal protein, renal dysfunction, hypercalcemia, and impaired normal antibody production.

Common Markers: CD38, CD138, BCMA (TNFRSF17), SLAMF7, and monoclonal immunoglobulin/light-chain expression.
Scientific Papers found: Click to Expand⟱
7437- CYN,    Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma
- in-vitro, Mye, AMO1 - in-vivo, Mye, NA - in-vitro, Mye, KMS11 - in-vitro, Mye, JJN3 - in-vitro, Mye, MolP8 - in-vitro, Mye, L363 - in-vitro, Mye, H929
tumCV↓, cMyc↓, STAT3↓, Akt↓, ERK↓, TumCCA↑, DNAdam↑, PARP1↑, AIF↑, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   STAT3↓, 1,   TumCG↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:92  Cells:%  prod#:%  Target#:35  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page